DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 9, 2020, regarding events occurring on January 7, 2020. DarioHealth Corp. is a Delaware corporation with principal executive offices in Caesarea, Israel. The company's common stock and warrants trade on The Nasdaq Capital Market under the symbols DRIO and DRIOW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is a significant restructuring of senior leadership roles effective January 13, 2020:
- Appointment: Richard Anderson was appointed President and General Manager of North America.
- Reassignment: Olivier Jarry was relieved of his duties as President and Chief Commercial Officer and reassigned to Senior Vice President of Strategy and Business Development.
Management Commentary and Compensation
In connection with Mr. Anderson's appointment, the Board approved the following compensatory arrangements:
- Base Salary: $335,000 annually.
- Incentive Bonus: Up to $250,000 annually, subject to milestones and performance targets.
- Equity: A stock option to purchase up to 90,000 shares of common stock, to be issued at a future date and price at the Board's discretion.
- Restrictions: Subject to a six-month non-competition and one-year non-solicitation provision.
Mr. Anderson brings extensive experience from Catasys, Inc., where he served as President and COO until December 2019, and previously held CFO roles at Clearant, Inc. and Intellect Capital Group.
Investor Verification Checklist
- Verify the effective date of the leadership transition (January 13, 2020).
- Confirm the specific terms and exercise price of the 90,000 stock options granted to Mr. Anderson once issued.
- Review the specific performance milestones required to achieve the $250,000 annual bonus.
- Assess the strategic rationale for reassigning Mr. Jarry from the President role to Strategy and Business Development.